- Orphazyme A/S ORPH plans an approximate two-thirds reduction in its global workforce due to a restructuring, aiming to advance its corporate strategy and the development of arimoclomol for Niemann-Pick disease type C (NPC).
- The company further said it remains committed to pursuing regulatory approval in Europe and assessing a path forward for arimoclomol in the U.S. after being hit by a Complete Response Letter from the FDA last week.
- NPC is a rare, genetic, progressively debilitating, and often fatal neurovisceral disease.
- Regarding its trading, Orphazyme said its financial outlook remains unchanged for 2021.
- With the planned restructuring and resulting cost savings, the company intends to free resources.
- Concurrently, the company announced 24-month interim results of an open-label extension trial for arimoclomol in NPC.
- The data were shared at the Parseghian Scientific Conference for Niemann-Pick disease type C Research.
- A slowing of progression from baseline was observed through 36 months in participants who received arimoclomol from the start of the double-blind phase (mean change, 3.5 points).
- The effect was consistent across pre-specified subgroups, including those treated with miglustat among participants more than four years of age.
- Also, slowing of progression through 24 months was observed in those participants who initiated arimoclomol treatment upon entering the open-label period (mean change, 0.9 points).
- Price Action: ORPH shares are down 1.78% at $7.71 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
